DMGSA advised on the sale of control of the Curitiba-based company NeoOrtho to the Swiss multinational Medartis, part of the Straumann Group, in a deal that was signed on Monday (17). Medartis, one of the world's leading manufacturers and suppliers of medical devices for surgical fixation of fractures, has acquired 51% of NeoOrtho, a Brazilian company that is a benchmark in orthopaedic solutions, headed by Paraná businessman Dr Geninho Thomé and his sons João Alfredo Thomé and José Guilherme Thomé. The value of the acquisition was not announced by the companies.
“A deal of this complexity usually takes several months, but this one was negotiated and signed in less than 60 days; the parties already knew each other from a previous transaction, which shortened some typical discussions in M&A processes,” says lawyer Gabriel Zugman, the DMGSA partner responsible for the M&A area who led the legal negotiation on the selling side.
The acquisition process should be finalized by the end of April so that sales can then be leveraged with Medartis' participation. Under the agreement, announced today in Switzerland and Brazil, Medartis will be able to increase its stake to 100 per cent of NeoOrtho over the next four years. As part of the transaction, Medartis is also acquiring a state-of-the-art modular plant, which is scheduled to begin operations at the end of 2025. The investment marks a strategic entry by the Swiss multinational into Latin America's hotly contested prosthetics market in the standard segment.
The sellers were advised on the transaction by DMGSA - Domingues Sociedade de Advogados, with the participation of partner Gabriel Zugman and lawyers Luciana David and Rodrigo Coppla.
The buyer was advised by Lefosse Advogados.